Back to Gene
HSPB8 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

HSPB8 gene

The HSPB8 gene provides instructions for creating a heat shock protein that helps protect cells from stress and maintains the structural integrity of nerve cells.

Normal Function

The HSPB8 gene provides instructions for making a protein called heat shock protein beta-8. This protein belongs to the heat shock protein family, which protects cells under stress from factors such as infection, inflammation, toxins, heat, injury, and disease. These proteins block signals that lead to cell self-destruction (apoptosis) and are involved in cell movement, stabilizing the cytoskeleton, folding newly produced proteins, and repairing damaged proteins.

Heat shock protein beta-8 is found throughout the body. In nerve cells (neurons), it interacts with heat shock protein beta-1 to help organize neurofilaments, which maintain the structure of the axon and allow for the efficient transmission of nerve impulses.

Health Conditions Related to Genetic Changes

Distal hereditary motor neuropathy, type II

Variants in the HSPB8 gene cause distal hereditary motor neuropathy, type II. This condition involves damage to motor neurons in the brain and spinal cord, leading to progressive weakness and muscle tissue loss (atrophy) in the feet and legs.

Research suggests that these variants produce an altered version of heat shock protein beta-8 that forms clusters (aggregates). These aggregates impair cell function, and the lack of functional protein leaves motor neurons vulnerable to stress and damage, eventually causing them to die.

Other Disorders

Variants in the HSPB8 gene are also associated with:

  • Charcot-Marie-Tooth disease
  • Myofibrillar myopathy

Other Names for This Gene

  • H11
  • heat shock protein beta-8
  • HSP22
  • HspB8
  • HSPB8_HUMAN
  • protein kinase H11

Frequently Asked Questions

Early symptoms often include gradual weakness or numbness in the feet and legs, difficulty walking, or a noticeable loss of muscle tone in the lower limbs. These changes usually appear in the second or third decade of life and may progress slowly over several years.
Currently, there is no cure, but supportive therapies such as physical therapy, occupational therapy, and orthotic devices can help maintain mobility. Research is ongoing into small‑molecule chaperones that may reduce protein aggregation, but these are still experimental.
Yes, at-risk relatives can undergo genetic testing. A positive result indicates a higher likelihood of developing symptoms, while a negative result usually means they are not carriers. Genetic counseling is recommended to discuss surveillance, lifestyle modifications, and reproductive options.===
Confirmation is done through a DNA test that looks for specific variants in the HSPB8 gene. The test requires a blood sample or a cheek swab, and the laboratory will sequence the gene to identify pathogenic changes. The results are typically available within 4–6 weeks.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA